Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 8, 2022- New results demonstrate MitraClip™ transcatheter edge-to-edge repair (TEER) is effective at treating leaky valves in people with secondary mitral regurgitation (MR)- Data from the first report on patients with a pacemaker lead across the tricuspid valve show TriClip™ and TriClip G4 TEER systems significantly reduce tricuspid regurgitation (TR) and substantially improve quality of life
-
Mar 1, 2022- TRICARE members now have faster, easier, and more convenient access to continuous glucose monitoring- Abbott’s FreeStyle Libre 2 system will now be on the brand-name formulary and available through retail pharmacies, home delivery and military treatment facilities
-
Feb 3, 2022- Abbott’s Proclaim™ dorsal root ganglion (DRG) neurostimulation system is the only FDA-approved DRG technology for the treatment of CRPS I and causalgia of the lower extremitiesi- UnitedHealthcare is the largest private health insurance company in the U.S, providing coverage for more than 44 million healthcare membersii
- Jan 26, 2022- Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent- Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter- Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent- Full-year 2021 sales growth of 24.5 percent; organic sales growth of 22.9 percent- Full-year 2021 GAAP diluted EPS from continuing operations growth of 58.2 percent; adjusted diluted EPS growth of 42.7 percent- R&D pipeline continues to deliver a steady cadence of new products, including several in large, fast-growing markets
- Jan 6, 2022- The company announced it's developing a new category of consumer biowearables called Lingo, which is being designed to track key signals in the body - such as glucose, ketones, and lactate - to help people better understand their general health and take action- Abbott is the first healthcare company to headline the Consumer Electronics Show, with Chairman and CEO Robert Ford presenting alongside scientists and inventors, industry partners, influencers and people who use Abbott health tech
- Dec 10, 2021- Dividend increased by 4.4%; follows a 25% increase in 2021- Board of directors also has authorized a new share repurchase program- Reflects Abbott's longstanding commitment to sustainable growth and shareholder returns
- Nov 16, 2021- Similac® 360 Total Care® is the first and only infant formula with a blend of five different human milk oligosaccharides[1] (HMOs) across the three categories of HMOs in breast milk[2], the closest prebiotic blend to that of breast milk and previously only available to infants who are breastfed- Similac 360 Total Care with five HMOs is designed to support babies' developing immune system in the gut, where 70% of the immune system resides, promote digestive health and provide building blocks for babies' developing brains
- Nov 15, 2021- Abbott included on DJSI for 17 consecutive years for strong environmental, social and governance (ESG) performance- Top score in the Health Care Equipment & Supplies sector reflects Abbott's 2030 Sustainability Plan focus on innovating for greater access to life-changing technologies and breaking down barriers to health equity
- Oct 20, 2021- Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent- GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent- Global COVID-19 testing-related sales were $1.9 billion in the third quarter- Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019- Continues to strengthen portfolio with several new product approvals
- Oct 18, 2021- Abbott becomes Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation- Partnership will include support of the first men's and women's and Academy football teams as well as support of the Real Madrid Foundation- Foundation supports 65,000 children per year across 80 countries through education in sportsmanship, teamwork, respect, and health and nutrition- Partnership supports Abbott's commitment to address global malnutrition over the next decade
-
Sep 29, 2021- Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients worldwide- Abbott’s PFO closure technology helps to prevent blood clots from passing from the right to left side of the heart from where they can travel to the brain and cause a stroke- The Talisman system offers the industry's widest range of device sizes in the U.S. and the occluder comes pre-attached to the delivery cable, making the device easier for physicians to use
Aug 2, 2021- FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone[1] every minute with optional real-time glucose alarms[2]- The FreeStyle Libre 2 app enables kids (ages 4 and older) and adults to easily share their glucose data with parents and other caregivers via the LibreLinkUp[3] app- Free to download on the App Store, the FreeStyle Libre 2 iOS app will be available soon- Jul 22, 2021- Sales growth of 39.5 percent; organic sales growth of 35.0 percent- GAAP diluted EPS from continuing operations growth of 120.0 percent; adjusted diluted EPS growth of 105.3 percent- Second-quarter sales, excluding COVID-19 testing-related sales, grew 12.3 percent on a reported basis and 11.3 percent on an organic basis compared to sales in 2019- Achieved strong sales growth across all four major business areas- Full-year forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis
- Jun 25, 2021- Comparative data presented at the American Diabetes Association 81st Scientific Sessions show Abbott's diabetes technology delivers the same reductions of HbA1c and acute complications(1,2) as the competitor systems while reaching a much wider, more diverse population- Priced at a third of the cost of other available continuous glucose monitoring systems(3), data suggests increasing use of FreeStyle Libre system could save Medicaid millions annually(4) by reducing costly complications- The groundbreaking FreeStyle Libre portfolio has been extensively studied with real-world data from more than 1 million users(5) and clinical evidence, showing it helps people with diabetes significantly improve their health and quality of life(6)
Jun 22, 2021Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit- Abbott's summer program is the American Council on Education's first high school STEM internship eligible for post-secondary education credit recommendation- First-of-its-kind college credit opportunity provides model other companies can follow to give students a head start on earning STEM degrees- Students who successfully complete Abbott's internship after their senior year of high school are eligible to apply for credit from their educational institutions- Jun 3, 2021- Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic's decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD)- Access to MCS devices are critical for advanced heart failure patients and can improve survival, clinical outcomes and quality of life- Abbott is working with physicians and health systems to ensure supply of left ventricular assist devices (LVADs) alongside training and education for implanting physicians now offering Abbott's HeartMate 3™ to their patients
-
May 12, 2021- Newly issued guidance from the U.S. Centers for Disease Control and Prevention now accepts rapid, self-administered testing option that meet its criteria- United customers can depart the U.S. with the Abbott BinaxNOW™ Home Test in their carry-on bag and administer the test via the eMed digital health platform to re-enter the U.S.
-
Apr 26, 2021- New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)- Ultreon 1.0 Software helps physicians automatically detect and quantify blood vessel characteristics, giving them better insights for optimal patient treatment- Platform offers advanced imaging features when combined with the Dragonfly OpStar™ imaging catheter used to access complex anatomy
- Apr 20, 2021- Sales growth of 35.3 percent; organic sales growth of 32.9 percent- GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent- All four major businesses achieved strong sales growth in the quarter- Projected full-year EPS remains unchanged; reflects growth of more than 35 percent
Mar 31, 2021- FDA Emergency Use Authorization permits asymptomatic, non-prescription, over-the-counter self use for people with or without symptoms- The BinaxNOW COVID-19 Self Test is identical to the professional-use test, used since August 2020, bringing the most studied and widely used rapid antigen test to retail shelves across the country- BinaxNOW Self Test will be available nationwide and in large quantities at major food, drug and mass merchandiser retailers nationally and will be priced affordably, similar to common over-the-counter (OTC) tests- Together with vaccines, serial testing of asymptomatic people will help restore a sense of safety in everyday settings where people gather- Asymptomatic multi-test authorization also applies to BinaxNOW professional-use test- Mar 11, 2021- The Abbott Pandemic Defense Coalition is a first-of-its-kind global scientific network dedicated to the early detection of, and rapid response to, future pandemic threats- The coalition builds on Abbott's decades of leadership in virus surveillance and helps to analyze virus samples for unknown diseases and detect mutations and variants including for COVID-19- Abbott is bringing together global collaborators specializing in identification of unknown diseases, surveillance, virus sample collection, testing and sequencing- Abbott will rapidly develop tests that can be used to help identify, isolate and contain outbreaks when potential new virus threats are identified
- Mar 5, 2021-- Abbott's Alinity™ m Resp-4-Plex assay will allow healthcare workers to test for four viruses in one test, a critically important tool as flu presents with similar symptoms-- The test helps save on much-needed testing supplies since it allows for testing for all four viruses with one swab-- Assay will run on Abbott's most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes-- Abbott also received updated EUA for asymptomatic usage of its Alinity m SARS-CoV-2 assay
- Mar 2, 2021- Study of more than 10,000 people identifies a rare group with controlled HIV in the Democratic Republic of Congo, suggesting additional research could uncover links between natural virus suppression and future treatments- Discovery is a result of Abbott's continued virus hunting efforts, which also uncovered a new strain of HIV in 2019- Abbott's decades of work in global viral surveillance has advanced the understanding of HIV and allowed the company to quickly respond to the COVID-19 pandemic with its diagnostic tests
- Jan 27, 2021- Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales- Sales growth of 28.7 percent; organic sales growth of 28.4 percent- GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent- Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020- R&D pipeline continues to be highly productive, delivering ground-breaking innovations and a steady cadence of important new products across all business areas- Issues 2021 EPS growth forecast of more than 35 percent
- Jan 26, 2021- Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic- Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers- Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision- Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology- Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads- Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends- Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide
- Jan 20, 2021- New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population
- Dec 22, 2020- 88% of Americans say it's important for COVID-19 testing to work in support of vaccine rollout- Americans agree an authorized vaccine will not change the environment overnight, indicating a need for ongoing layered protections- Despite belief in effectiveness of vaccination and testing, there is concern that other precautionary measures will decline
- Dec 17, 2020- Abbott's HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure- This life-saving technology provides new treatment option for underserved population
Dec 16, 2020- First at-home, virtually guided service to bring rapid, reliable and affordable testing into the home where the result is delivered in minutes- Abbott and eMed™ expect to deliver and administer 30 million BinaxNOW™ tests in the first quarter of 2021, with an additional 90 million in the second quarter- $25 cost for the test and service is the lowest available for at-home testing, which supports the home user to ensure a successful testing process- BinaxNOW is a highly portable, easy-to-use, 15-minute antigen test with no instrument that detects the virus when people are most infectious, which is critically important in slowing the spread of the virus- Service uses Abbott's complementary NAVICA™ app to enable the testing process and display authenticated BinaxNOW test results verified by a trained guide - and supports consumer confidence in testing at home- Dec 11, 2020- Increase reflects strength and sustainability of Abbott's diversified business- Dividend increased for 49th consecutive year- Abbott remains an S&P 500 Dividend Aristocrat
-
Dec 2, 2020- A survey, sponsored by Abbott, reveals three in four cardiologists worry the COVID-19 pandemic has restricted heart failure patients’ ability to manage their condition- In response to COVID-19, Abbott is partnering with physicians on tools and training programs to support the diagnosis and treatment of cardiovascular disease
- Nov 18, 2020- Abbott is committing $5 million over three years to the American Diabetes Association (ADA) to help close the health disparities gap for underserved diabetes communities, especially people of color and lower-income Americans
- Oct 21, 2020- Third-quarter sales growth of 9.6 percent; organic sales growth of 10.6 percent- Sales growth in Medical Devices and Diagnostics improved significantly versus prior quarter- Continues to strengthen portfolio with several recent new product approvals, including FreeStyle Libre 3, Libre Sense Glucose Sport Biosensor and MitraClip G4 heart device